MedTrace Logo

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment

NCT02396862 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 272

Last updated 2019-03-27

No results posted yet for this study

Summary

The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.

Conditions

Interventions

DRUG

Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)

Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
16 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-09
Primary Completion
2018-01-17
Completion
2018-03-26

Countries

  • United States
  • Japan
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02396862 on ClinicalTrials.gov